↓ Skip to main content

Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy

Overview of attention for article published in Cancer Discovery, April 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (86th percentile)
  • High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

twitter
7 X users
patent
13 patents

Citations

dimensions_citation
194 Dimensions

Readers on

mendeley
228 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy
Published in
Cancer Discovery, April 2016
DOI 10.1158/2159-8290.cd-15-0944
Pubmed ID
Authors

Stephen J. Blake, Kimberley Stannard, Jing Liu, Stacey Allen, Michelle C.R. Yong, Deepak Mittal, Amelia Roman Aguilera, John J. Miles, Viviana P. Lutzky, Lucas Ferrari de Andrade, Ludovic Martinet, Marco Colonna, Kazuyoshi Takeda, Florian Kühnel, Engin Gurlevik, Günter Bernhardt, Michele W.L. Teng, Mark J. Smyth

Abstract

CD96 has recently been shown as a negative regulator of mouse NK cell activity, with Cd96-/- mice displaying hyper-responsive NK cells upon immune challenge. In this study we have demonstrated that blocking CD96 with a monoclonal antibody inhibited experimental metastases in three different tumor models. The anti-metastatic activity of anti-CD96 was dependent on NK cells, CD226 (DNAM-1) and IFN-γ, but independent of activating Fc receptors. Anti-CD96 was more effective in combination with anti-CTLA4, anti-PD1 or doxorubicin chemotherapy. Blocking CD96 in Tigit-/- mice significantly reduced experimental and spontaneous metastases compared to its activity in WT mice. Co-blockade of CD96 and PD1 potently inhibited lung metastases, with the combination increasing local NK cell IFN-γ production and infiltration. Overall these data demonstrate that blocking CD96 is a new and complementary immunotherapeutic strategy to reduce tumor metastases.

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 228 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Australia 2 <1%
France 2 <1%
United States 1 <1%
Germany 1 <1%
Unknown 222 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 48 21%
Student > Ph. D. Student 43 19%
Student > Master 21 9%
Other 18 8%
Student > Bachelor 17 7%
Other 35 15%
Unknown 46 20%
Readers by discipline Count As %
Immunology and Microbiology 52 23%
Biochemistry, Genetics and Molecular Biology 44 19%
Medicine and Dentistry 32 14%
Agricultural and Biological Sciences 26 11%
Pharmacology, Toxicology and Pharmaceutical Science 7 3%
Other 16 7%
Unknown 51 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 February 2023.
All research outputs
#2,655,927
of 25,374,917 outputs
Outputs from Cancer Discovery
#1,060
of 4,062 outputs
Outputs of similar age
#42,081
of 315,146 outputs
Outputs of similar age from Cancer Discovery
#12
of 79 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,062 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.6. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,146 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 79 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.